Crossmark

Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study

Crossref DOI link: https://doi.org/10.1186/s12885-018-4067-5

Published Online: 2018-02-05

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ozaki, Yukinori

Shindoh, Junichi

Gonoi, Wataru

Nishioka, Yujiro

Kondoh, Chihiro

Tanabe, Yuko

Matoba, Shuichiro

Kuroyanagi, Hiroya

Hashimoto, Masaji

Takano, Toshimi
Funding

Funding for this research was provided by:

JSPS KAKENHI Grant (No. 26861063)
More Information

Article History

Received: 19 October 2016

Accepted: 29 January 2018

First Online: 5 February 2018

Ethics approval and consent to participate

: We have obtained the approval of the ethics committee in Toranomon Hospital. Written informed consent from the human subjects is deemed unnecessary by the IRB in Toranomon Hospital according to national regulations, and we provide the information on the website (ExternalRef removed).

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below